Currently, 1 in 59 children are diagnosed with Autism Spectrum Disorder (ASD) in the United States. In Wisconsin, 1 in 92 children are diagnosed with ASD (Christensen et al., 2016). Despite the high prevalence of children diagnosed with ASD, disparities in diagnosis and access to interventions continue to exist for families from ethnically and racially diverse backgrounds (Durkin, et al. 2017). The reasons for these disparities are not straightforward and preliminary evidence suggests that language barriers and cultural beliefs about the behaviors associated with ASD may influence access to care for diverse populations (Newschaffer, 2017).The Centers for Disease Control and Prevention "Learn the Signs. Act Early."(LTSAE) campaign is designed to help families understand developmental milestones, track development and act early when they have a concern. The LTSAE campaign has the potential of reducing disparities in the early identification of ASD; however, little is known about the effectiveness of the campaign with diverse populations. The purpose of this project is to conduct an integrated literature review about the LTSAE campaign in racially and ethnically diverse groups.
The objectives of this research is the evaluation of new drug candidates to treat Dravet Syndrome (DS), also known as severe myoclonic epilepsy of infancy, which is one of the most pharmacoresistant epilepsy syndromes. Therefore, we will be using Scn1a +/− heterozygous knockout mice as animal model for DS. Seizures induced by heat will be recorded for vehicle and drug treated groups of mice. Furthermore, tonic-clonic seizures will be recorded by video.
The objective of this research is to determine the cyto- and genotoxicity of new drug candidates. Therefore, we are using cultured human cell lines and expose them to increasing concentration of compounds. We will use luminescence and stains to determine genotoxicity and cytotoxicity.